Immunology Investor Event
Anti-IL-13/OX40L bispecific NanobodyⓇ molecule
Potential to break efficacy ceilings in Type 2 Inflammation
IL-33
TSLP
IL-25
Chemokines
Tissue Inflammation
Tissue Remodeling
OX40L
IL-13
OX40
Th22
Th17
Th2
mate
cells
IL-22
IL-17
IL-5
IL-4
Neutrophil
Eosinoph
B cell
IgE
Gene Expression Levels
in Skin
sanofi
Control
Allergen+
Placebo
Allergen+
SAR443726
Allergen+
a-IL-13 mAb
Allergen+
a-OX40L mAb
House Dust Mite induced skin inflammation in
a model of Atopic Dermatitis demonstrates potent
reversal of reactions by SAR443726
Anti-IL-13/OX40L
NanobodyⓇ VHH with potent
picomolar binding affinity to
both IL-13 and OX40L
Albumin-binding designed
to extend half-life
Enhanced efficacy of
bispecific NanobodyⓇ VHH in
several preclinical models of
Type 2 biology & diseases
46 Immunology Investor Event
Phase 1 in healthy subjects ongoing; Indication: ADView entire presentation